$ATEC

MCGINNIS KAREN K sold $48K of ATEC

MCGINNIS KAREN K sold 6,050 shares of Alphatec Holdings, Inc. (ATEC) at $8.01 on 2026-06-11 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · MCGINNIS KAREN K
Published Jun 12, 2026, 9:54 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 12, 2026, 9:57 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ATEC
Neutral
medium confidence
Mentioned
$ATEC
Relevance
2/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ATECNeutralLow
01

Why it matters

The disclosure confirms a director open-market sale of 6,050 shares at $8.01/share, executed under a pre-arranged 10b5-1 plan; it does not include any new operational, financial, or regulatory developments.

02

Market read

Traders may monitor for incremental insider activity, but this specific filing is unlikely to drive a major repricing without additional catalysts.

03

What to watch

Check for clustering of insider sales/buys around the same period; a single planned sale is less informative than a pattern.

Relevance 2/10Novelty 6/10Timing: Filed 2026-06-12; sale executed 2026-06-11

Background

The filing is an SEC Form 4 insider transaction for Alphatec Holdings, Inc. (ATEC).

Company-level read

Ticker impact

$ATECNeutralMedium confidence
Context

Alphatec director Karen McGinnis sold 6,050 shares in an open-market transaction on 2026-06-11 under a pre-arranged 10b5-1 plan.

Expected impact

Likely limited/short-lived impact; treat as low-signal unless follow-on insider activity accelerates.

Evidence & confidence

Form 4 is a primary disclosure, but the article provides no new company-specific catalyst beyond a planned sale.

Market effects

No sector-level read-across; this is company-specific insider transaction data only.

None indicated.

None indicated.

Counterpoint

10b5-1 sales can be purely mechanical; the market may overreact to the headline “sell” despite no change in fundamentals.

Key entities

  • Alphatec Holdings, Inc.

    Company whose director insider sale is disclosed on SEC Form 4.

  • Karen McGinnis

    Director who sold 6,050 shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ATECMedAI 8/10

Alphatec (ATEC) Q2 2026 Earnings Call Transcript

Alphatec Holdings (NASDAQ:ATEC) reported Q2 2026 revenue of $214 million, up 15% year over year, with surgical revenue at $196 million, up 17%. Adjusted EBITDA rose to $36 million, up 53%, with GAAP gross margin 72.2%. Management reaffirmed full-year revenue guidance near $882 million and raised adjusted EBITDA guidance to about $140 million.

$ATECMed

Alphatec (ATEC) Q2 2026 Earnings Call Transcript

Alphatec Holdings (ATEC) reported Q2 2026 revenue of $214 million, up 15% year over year, with surgical revenue at $196 million, up 17%. Adjusted EBITDA rose 53% to $36 million, and GAAP gross margin was 72.2%. Management reaffirmed full-year revenue guidance near $882 million and raised adjusted EBITDA guidance to about $140 million.

$ATECMed

Alphatec Holdings, Inc. Q2 2026 Earnings Call Summary

Alphatec Holdings (ATEC) reported Q2 2026 results driven by 24% growth in new surgeon adoption and 20% procedural volume growth, lifting revenue 15%. Management kept full-year surgical revenue guidance at $805M and raised adjusted EBITDA guidance to $140M. It expects Q3 free cash flow of $4M to $6M and cites margin gains from inventory and supply chain efficiency.

$ATECMed

Alphatec Holdings, Inc. (ATEC): Results of Operations and Financial Condition

Alphatec Holdings, Inc. (ATEC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ATEC Reports Second Quarter Financial Results Total revenue of $214 million, up 15% year-over-year Surgical revenue of $196 million increased 17%, driven by 20% case volume growth Company reaffirms 2026 revenue outlook CARLSBAD, Calif., August 4, 2026 – Alphatec Hold